SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.

导出 OA

翻译打印收藏纠错

作者： Ruben A,Mesa ^[1] ; Jean-Jacques,Kiladjian ^[1] ; John V,Catalano ^[1] ; Timothy,Devos ^[1] ; Miklos,Egyed ^[1] ; Andrzei,Hellmann ^[1] ; Donal,McLornan ^[1] ; Kazuya,Shimoda ^[1] ; Elliott F,Winton ^[1] ; Wei,Deng ^[1] ; Ronald L,Dubowy ^[1] ; Julia D,Maltzman ^[1] ; Francisco,Cervantes ^[1] ; Jason,Gotlib ^[1]

作者单位： Ruben A. Mesa, Mayo Clinic Cancer Center, Scottsdale, AZ; Jean-Jacques Kiladjian, Saint-Louis Hospital (Assistance Publique-Hôpitaux de Paris) and Paris Diderot University, Paris, France; John V. Catalano, Frankston Hospital and Monash University, Melbourne, Victoria, Australia; Timothy Devos, University Hospital Leuven and Katholieke Universiteit Leuven, Leuven, Belgium; Miklos Egyed, Kaposi Mor Teaching Hospital, Kaposvar, Hungary; Andrzei Hellmann, Medical University of Gdańsk, Gdańsk, Poland; Donal McLornan, Guy's and St Thomas' National Health Service Foundation Trust, London, United Kingdom; Kazuya Shimoda, University of Miyazaki, Miyazaki, Japan; Elliott F. Winton, Emory University School of Medicine, Atlanta, GA; Wei Deng, Ronald L. Dubowy, and Julia D. Maltzman, Gilead Sciences, Foster City; Jason Gotlib, Stanford Cancer Institute, Stanford, CA; and Francisco Cervantes, Hospital Clinic, Institut D'Investigacions Biomèdiques August Pi I Sunyer, University of Barcelona, Barcelona, Spain. ^[1]